Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Total Debt: 2009-2022

Historic Total Debt for Amicus Therapeutics (FOLD) over the last 13 years, with Dec 2022 value amounting to $21.4 million.

  • Amicus Therapeutics' Total Debt fell 32.50% to $13.0 million in Q2 2023 from the same period last year, while for Jun 2023 it was $13.0 million, marking a year-over-year decrease of 32.50%. This contributed to the annual value of $21.4 million for FY2022, which is 13.32% up from last year.
  • Per Amicus Therapeutics' latest filing, its Total Debt stood at $21.4 million for FY2022, which was up 13.32% from $18.9 million recorded in FY2021.
  • Amicus Therapeutics' 5-year Total Debt high stood at $147.4 million for FY2019, and its period low was $8.9 million during FY2020.
  • For the 3-year period, Amicus Therapeutics' Total Debt averaged around $16.4 million, with its median value being $18.9 million (2021).
  • In the last 5 years, Amicus Therapeutics' Total Debt soared by 1,646.83% in 2018 and then crashed by 93.96% in 2020.
  • Amicus Therapeutics' Total Debt (Yearly) stood at $146.7 million in 2018, then rose by 0.44% to $147.4 million in 2019, then tumbled by 93.96% to $8.9 million in 2020, then surged by 112.36% to $18.9 million in 2021, then increased by 13.32% to $21.4 million in 2022.